about
Inulin, a flexible oligosaccharide. II: Review of its pharmaceutical applicationsInulin, a flexible oligosaccharide I: Review of its physicochemical characteristicsEffect of inhaler design variables on paediatric use of dry powder inhalersDrug content effects on the dispersion performance of adhesive mixtures for inhalationNew mechanisms to explain the effects of added lactose fines on the dispersion performance of adhesive mixtures for inhalationTolerability and Pharmacokinetic Evaluation of Inhaled Dry Powder Tobramycin Free Base in Non-Cystic Fibrosis Bronchiectasis PatientsThe Production of a Stable Infliximab Powder: The Evaluation of Spray and Freeze-Drying for ProductionSimplifying influenza vaccination during pandemics: sublingual priming and intramuscular boosting of immune responses with heterologous whole inactivated influenza vaccine.Development of stable influenza vaccine powder formulations: challenges and possibilitiesEnhanced pulmonary immunization with aerosolized inactivated influenza vaccine containing delta inulin adjuvant.Preservation of the immunogenicity of dry-powder influenza H5N1 whole inactivated virus vaccine at elevated storage temperatures.Needle-free influenza vaccination.Evaluating the immunogenicity and safety of a BiondVax-developed universal influenza vaccine (Multimeric-001) either as a standalone vaccine or as a primer to H5N1 influenza vaccine: Phase IIb study protocol.Characterization of inhalation aerosols: a critical evaluation of cascade impactor analysis and laser diffraction technique.Design and application of a new modular adapter for laser diffraction characterization of inhalation aerosols.Spray freeze drying to produce a stable Delta(9)-tetrahydrocannabinol containing inulin-based solid dispersion powder suitable for inhalation.Inhalation of tobramycin in cystic fibrosis. Part 2: optimization of the tobramycin solution for a jet and an ultrasonic nebulizer.The choice of a compressor for the aerosolisation of tobramycin (TOBI) with the PARI LC PLUS reusable nebuliser.The rate of drug particle detachment from carrier crystals in an air classifier-based inhaler.The mode of drug particle detachment from carrier crystals in an air classifier-based inhaler.Design and in vitro performance testing of multiple air classifier technology in a new disposable inhaler concept (Twincer) for high powder doses.The effect of carrier surface treatment on drug particle detachment from crystalline carriers in adhesive mixtures for inhalation.Dry powder inhalation of colistin sulphomethate in healthy volunteers: A pilot study.In vitro performance testing of the novel Medspray wet aerosol inhaler based on the principle of Rayleigh break-upComparative in vitro evaluation of four corticosteroid metered dose inhalers: Consistency of delivered dose and particle size distribution.A centrifuge method to measure particle cohesion forces to substrate surfaces: the use of a force distribution concept for data interpretation.Pharmacokinetics of a prototype formulation of sublingual testosterone and a buspirone tablet, versus an advanced combination tablet of testosterone and buspirone in healthy premenopausal women.Effect of nebulized colistin sulphate and colistin sulphomethate on lung function in patients with cystic fibrosis: a pilot study.Breaking of scored tablets: a review.The formation of oxytocin dimers is suppressed by the zinc-aspartate-oxytocin complex.A new strategy to stabilize oxytocin in aqueous solutions: I. The effects of divalent metal ions and citrate buffer.Physical and immunogenic stability of spray freeze-dried influenza vaccine powder for pulmonary delivery: comparison of inulin, dextran, or a mixture of dextran and trehalose as protectants.A user-friendly model for spray drying to aid pharmaceutical product development.In vitro evaluation of the DP-4M PennCentury insufflator.Benefits of different drug formulations in psychopharmacology.Can Patients with Parkinson's Disease Use Dry Powder Inhalers during Off Periods?Gastrointestinal pH and Transit Time Profiling in Healthy Volunteers Using the IntelliCap System Confirms Ileo-Colonic Release of ColoPulse TabletsSingle dose sublingual testosterone and oral sildenafil vs. a dual route/dual release fixed dose combination tablet: a pharmacokinetic comparison.Pharmacoeconomic review of recombinant human DNase in the management of cystic fibrosis.Improved dissolution behavior of lipophilic drugs by solid dispersions: the production process as starting point for formulation considerations.
P50
Q26782865-8239D758-C364-4A70-9B21-0FA30FBA5C7FQ27006571-19943288-3301-4C9E-BA3E-4DB6A73645FBQ27324278-AF3851F0-1632-472F-A799-A4FA44437C51Q28535334-C8391095-F4B8-4646-858F-1FDFDC020B54Q28539263-BAC281B3-0A48-4112-81F1-034F331E9331Q28550641-D2C94F01-BA59-4DCB-9F35-411BF47944A4Q28554493-1610FC4B-6077-4A22-940B-95CB8AD596BEQ30358537-F4977CDB-BD46-4C23-BDCE-8917CA043566Q30368221-AEFC6ECC-7D2D-4B78-B73F-CD2936809B90Q30369258-2ECB34B1-D6E6-4189-8BF3-D414BD1E12F7Q30386212-F62FB765-4FAF-47B1-AE04-B65CF29C977CQ30394326-A427DE5B-E9F6-4A46-9F07-E4B0074055BFQ30399951-AEF66780-CE3E-4480-A1E7-376C81696F7EQ30756423-A952DF9C-C8EF-40E7-AE30-50F130BD4C12Q30756541-0C2465D3-0F26-41B1-B0AA-62CE72D132EBQ30795362-68FE98DE-9C12-4029-8F5C-E86A505924D9Q30801433-949AD447-B9BB-4AB4-BE5A-15B030FFA3E0Q31029590-938C86FB-A7BB-4877-AF90-0C1CAD4554D6Q31141040-DACD8617-E743-4FD8-ADE6-69568D825325Q31141044-05A1DE07-0EE7-4F9A-A3B8-79F9F1AB4921Q33241662-9CDF3A40-845A-4332-AFCC-BFCFA34CA14CQ33254537-86D90885-7B0A-45DC-9108-22885C04649CQ33267040-B6C19E30-21B7-4897-99DA-CF4E37EF47F5Q33309292-57D68C41-AAA6-4735-8565-7A618D74D16FQ33415895-638CAFB6-C4F1-4C42-9050-D721B8983FB8Q33562402-81DA878F-416A-443E-8540-D4609444A355Q33804785-E9784C47-5F95-4E20-9445-A4047AA881D0Q34355420-64014C1A-E5D6-4AB7-9EAB-8F7ADADD7C74Q34552796-4A2D247F-DA5D-4881-A7D9-DF8B3ADE4488Q34669877-4E79D83A-1404-4653-93BD-A32594FD3E71Q34901001-F846E1E8-3ADF-47E5-B29D-1BC5D3885372Q34914845-6C519603-8BE3-4093-B536-C6611928C6E9Q34989995-EFD79BA0-E4F9-40CC-86C3-14390CD2D1B8Q35201014-F1514EB9-4C10-4F25-A361-3DC3D0765B34Q35556168-04D7CB2D-0B3E-475E-88CC-15A715270CD5Q35691050-08BB0192-BC57-4B98-9707-C6B8A81B1286Q35692281-E42F6EE5-A532-4150-8814-7A1C4313D009Q36924701-A9F95765-AFCA-465D-8B0D-EBDC1F9EDC28Q37609204-ED26FC87-2A77-453C-9C2B-C7DAF6FD2AA9Q37896655-872CBFEA-AD63-4CC3-A237-18CDD55AE925
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Henderik Frijlink
@nl
Henderik W Frijlink
@ast
Henderik W Frijlink
@en
Henderik W Frijlink
@es
type
label
Henderik Frijlink
@nl
Henderik W Frijlink
@ast
Henderik W Frijlink
@en
Henderik W Frijlink
@es
altLabel
H. Frijlink
@nl
H.W. Frijlink
@nl
Henderik W Frijlink
@nl
prefLabel
Henderik Frijlink
@nl
Henderik W Frijlink
@ast
Henderik W Frijlink
@en
Henderik W Frijlink
@es
P106
P1153
7004545002
P31
P496
0000-0001-7901-8198
P7449
PRS1239540